TWI887362B - 抗內皮脂肪酶抗體之配製物 - Google Patents

抗內皮脂肪酶抗體之配製物 Download PDF

Info

Publication number
TWI887362B
TWI887362B TW110106493A TW110106493A TWI887362B TW I887362 B TWI887362 B TW I887362B TW 110106493 A TW110106493 A TW 110106493A TW 110106493 A TW110106493 A TW 110106493A TW I887362 B TWI887362 B TW I887362B
Authority
TW
Taiwan
Prior art keywords
seq
antibody
formulation
ser
drug formulation
Prior art date
Application number
TW110106493A
Other languages
English (en)
Chinese (zh)
Other versions
TW202146046A (zh
Inventor
沙亞爾 曼奴亥 帕泰爾
史瓦普尼爾 克胡沙爾 潘沙爾
Original Assignee
美商麥迪紐有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商麥迪紐有限責任公司 filed Critical 美商麥迪紐有限責任公司
Publication of TW202146046A publication Critical patent/TW202146046A/zh
Application granted granted Critical
Publication of TWI887362B publication Critical patent/TWI887362B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW110106493A 2020-02-24 2021-02-24 抗內皮脂肪酶抗體之配製物 TWI887362B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062980658P 2020-02-24 2020-02-24
US62/980,658 2020-02-24

Publications (2)

Publication Number Publication Date
TW202146046A TW202146046A (zh) 2021-12-16
TWI887362B true TWI887362B (zh) 2025-06-21

Family

ID=77492003

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110106493A TWI887362B (zh) 2020-02-24 2021-02-24 抗內皮脂肪酶抗體之配製物

Country Status (8)

Country Link
US (1) US20230131324A1 (cg-RX-API-DMAC10.html)
EP (1) EP4110290A4 (cg-RX-API-DMAC10.html)
JP (1) JP7892560B2 (cg-RX-API-DMAC10.html)
CN (1) CN115297838A (cg-RX-API-DMAC10.html)
AU (1) AU2021227871A1 (cg-RX-API-DMAC10.html)
CA (1) CA3211692A1 (cg-RX-API-DMAC10.html)
TW (1) TWI887362B (cg-RX-API-DMAC10.html)
WO (1) WO2021173537A1 (cg-RX-API-DMAC10.html)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI357820B (en) * 2003-04-04 2012-02-11 Genentech Inc High concentration antibody and protein formulatio
TW201613982A (en) * 2014-09-11 2016-04-16 Shionogi & Co Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507808B2 (en) * 2002-12-12 2009-03-24 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
SMP200800064B (it) * 2006-04-21 2009-11-06 Novartis Ag Composizioni farmaceutiche di anticorpi anti-cd40 antagonista
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
PE20120359A1 (es) 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
WO2012076670A2 (en) * 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
WO2013086443A1 (en) * 2011-12-08 2013-06-13 Amgen Inc. Agonistic human lcat antigen binding proteins and their use in therapy
US20150239970A1 (en) * 2012-10-25 2015-08-27 Medimmune, Llc Stable, Low Viscosity Antibody Formulation
US9932591B2 (en) * 2013-12-18 2018-04-03 University Of Delaware Reduction of lipase activity in product formulations
CN106604744A (zh) * 2014-09-03 2017-04-26 免疫医疗有限公司 稳定的抗IL‑4R‑α抗体配制品
JP7377596B2 (ja) * 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI357820B (en) * 2003-04-04 2012-02-11 Genentech Inc High concentration antibody and protein formulatio
TW201613982A (en) * 2014-09-11 2016-04-16 Shionogi & Co Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase

Also Published As

Publication number Publication date
AU2021227871A1 (en) 2022-09-15
TW202146046A (zh) 2021-12-16
JP7892560B2 (ja) 2026-07-21
EP4110290A4 (en) 2024-06-05
JP2023514721A (ja) 2023-04-07
US20230131324A1 (en) 2023-04-27
EP4110290A1 (en) 2023-01-04
CN115297838A (zh) 2022-11-04
WO2021173537A1 (en) 2021-09-02
CA3211692A1 (en) 2023-09-02

Similar Documents

Publication Publication Date Title
KR102589598B1 (ko) 단클론 항체의 제형
JP6416841B2 (ja) 医薬製剤
CN102770157B (zh) 抗体的配制品
JP2020079242A (ja) 高濃度の抗vegf抗体を含有する安定状態のタンパク質溶液製剤
JP7089121B2 (ja) 高濃度の抗vegf抗体を含有するタンパク質溶液製剤
CN106061468B (zh) 包含TNFR和Fc区的融合蛋白的液体制剂
JP7398958B2 (ja) 安定的抗osmr抗体製剤
TW202034901A (zh) 抗體配方
AU2021250949A1 (en) Liquid Pharmaceutical Composition
JP2022519796A (ja) 抗pcsk9抗体を含む安定製剤
US20230131324A1 (en) Formulations of anti-endothelial lipase antibodies
CN118056572A (zh) 含有抗il-17抗体的稳定制剂
CN116172947A (zh) 一种含特异性结合vegf和ang2的双特异性抗体的药物组合物
HK40083646A (en) Formulations of anti-endothelial lipase antibodies
KR20230121797A (ko) 항-il5r 항체 제형
HK40103088A (en) Anti-il5r antibody formulations
WO2026102693A1 (zh) 一种pcsk9抗体及其应用
CN116077650A (zh) 一种稳定的新冠中和抗体的药物组合物及其应用
TW202541845A (zh) 穩定醫藥製劑